Raphael Pharmaceutical Inc.
RAPH· OTC
RAPHRaphael Pharmaceutical Inc.
Filed Aug 12, 2024 · 10-Q · 43 days after period end · 0001213900-24-067723
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$248.00K | -$417.00K | -$627.00K | -$387.00K |
| EPS Diluted | $0.01 | $0.03 | $0.05 | $0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Raphael Pharmaceutical Inc. · CIK 1415397 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 12, 2024 · 43 d after period end
